China Regenerative Medicine Intl : “Acornea” expands clinical applications Completed FDA registration

[Group News] China Regenerative Medicine International Limited (Stock Code: 8158.HK) "Acornea" expands clinical applications Completed FDA registration

(25 July, 2017 - Hong Kong) - China Regenerative Medicine International Limited ("CRMI" or the "Company," stock code: 8158.HK, together with its subsidiaries, collectively the "Group") is pleased to announce that the Group has actively expanding the clinical applications of its bioengineered cornea "Acornea" in ophthalmological surgeries. Recently, U.S. Food and Drug Administration ("FDA") approves biomaterial of Acornea to be use in production of drainage pouch for Tube-Shunt Surgery for Glaucoma. The approval from FDA greatly facilitates overseas business expansion strategy of the Group.

Mr. Chen Chunguo, CEO of China Regenerative Medicine International Limited said, "'Acornea' has brought the future to patients who has been suffering eye disease. The Group spares no effort to research and develop, so as to expand the ophthalmology indications of 'Acornea'. The approval from FDA allows the biomaterial of Acornea to be use in production of drainage pouch for Tube-Shunt Surgery for Glaucoma, which can effectively prevent from corrosion of the eye vessel. The Group believed the product could benefits 82,000 patients every year in U.S., Canada, Mexico and South America.

Acornea is the world's first bio-engineering cornea that has completed clinical trials and has been successfully launched to market, making China's leading position in regenerative medicine research of corneal disease in the world. The total effective rate of clinical trials of Acornea reached 94.44% with the healing effect close to donated cornea. In 2016, Acornea was reported by BBC as one of the five major scientific and technological revolutions from China, which make great contribution to the world. Its academic status makes China seize the initiative in the field of biomedical competition in the world.

As one of the most authoritative and influential drug regulatory agency in the world,

U.S. Food and Drug Administration has tighten the standard of drugs quality in recent years, while raising the entry threshold of overseas pharmaceutical products importation. The approval of FDA has also recognized the raw materials selection, production control, quality control and quality assurance of 'Acornea' in ophthalmology indications research and development have reached the world-class standards.

Looking forward, the Group will continue to focus on patients, and promote "Acornea" and other products into the global market, so as to benefit more patients with CRMI."

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited，listed on the GEM Board of The

Stock Exchange, stock code :8158. China Regenerative Medicine is a high-end new- technology enterprise, principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The Group has successfully evolved into a tissue engineering pioneer and has successfully industrialized regenerative medicine, as well as accomplished the research and development and commercialization platform of tissue engineering. The Group has applied for more than 140 domestic and overseas patents on three major business segments, namely tissue engineering, cell therapy, and cosmetics, including 'ActivSkin', the only tissue-engineered skin developed in China, and 'Acornea', the world's first bio-engineered cornea which completed its clinical trials. For more details, please visit www.crmi.hk